Japanese Trade Distributors Stock News

In early February 2026, Astellas Pharma raised its full-year revenue and profit guidance, citing stronger global sales of XTANDI and Mirabegron and favorable foreign exchange effects, while also resolving all U.S. Myrbetriq patent litigation through settlements totaling US$210,000,000 in cash and license payments from Lupin and Zydus. Shortly afterward, Evinova announced an AI-powered clinical development collaboration with Astellas, AstraZeneca and Bristol Myers Squibb, highlighting...

Kubota Corporation’s board meeting on February 12, 2026 approved a year-end dividend of ¥25 per share for 2025, confirmed capital infusion of ₹5 billion into Escorts Kubota Finance, and advanced stock-based compensation plans using treasury shares. On the same day, Kubota reported full-year 2025 earnings with slightly higher sales but lower net income, while issuing 2026 guidance that includes higher dividend expectations, highlighting a continued emphasis on shareholder returns despite...

Earnings update and why it matters for Daikin IndustriesLtd (TSE:6367) Daikin IndustriesLtd (TSE:6367) is back in focus after reporting nine month earnings to December 31, 2025, alongside fresh full year guidance that gives investors a clearer view of expected sales, profit and earnings per share. See our latest analysis for Daikin IndustriesLtd. The fresh guidance and nine month update come after a period where the share price has seen a 7.70% 7 day share price return and a 28.66% 1 year...

Shareholders might have noticed that Bridgestone Corporation ( TSE:5108 ) filed its annual result this time last week...

Charm Care Corporation's ( TSE:6062 ) stock showed strength, with investors undeterred by its weak earnings report. We...

As global markets grapple with AI disruption concerns and fluctuating economic indicators, Asia presents a unique landscape where small-cap stocks are gaining attention amidst broader market shifts. In this context, identifying promising stocks involves looking for companies that demonstrate resilience and adaptability in changing environments, often characterized by innovative strategies or niche market positions.

There's been a notable change in appetite for PeptiDream Inc. ( TSE:4587 ) shares in the week since its yearly report...

The market for Toray Industries, Inc.'s ( TSE:3402 ) shares didn't move much after it posted weak earnings recently. We...

The market was pleased with the recent earnings report from Bando Chemical Industries, Ltd. ( TSE:5195 ), despite the...

What Kajima’s guidance revision and earnings update mean for investors Kajima (TSE:1812) has drawn fresh attention after raising its full year earnings guidance and reporting higher sales, revenue and net income for the nine months to December 2025, driven by construction business performance. The new consolidated forecast now points to revenues of ¥3,030,000 million, operating income of ¥228,000 million and net income attributable to owners of parent of ¥170,000 million, with basic earnings...

Earlier this month, Takeda Pharmaceutical announced that the U.S. FDA accepted its New Drug Application and granted Priority Review for orexin agonist Oveporexton (TAK-861) in narcolepsy type 1, with a PDUFA decision expected in the third quarter of this year. This development highlights Takeda’s push into orexin-targeted neuroscience, aiming to address persistent symptoms in narcolepsy type 1 where many patients remain insufficiently treated. We’ll now examine how the FDA’s Priority Review...

Hikari Tsushin (TSE:9435) drew fresh attention after reporting nine month earnings to December 31, 2025, along with higher full year profit and dividend forecasts, citing foreign exchange gains and its policy of steadily returning cash to shareholders. See our latest analysis for Hikari Tsushin. Despite the earnings and dividend guidance news, Hikari Tsushin’s recent share price has been soft, with a 7 day share price return of a 5.74% decline and a 30 day share price return of a 4.4%...

Asahi Kasei (TSE:3407) is back on investors’ radar after its pharma arm and Alchemedicine moved endothelin A receptor antagonist AK1960 into Phase I trials for refractory conditions such as chronic kidney disease. See our latest analysis for Asahi Kasei. Those healthcare moves sit alongside fresh earnings guidance and recent results. The market has responded with a strong 30 day share price return of 16.66% and a 1 year total shareholder return of 81.82%, suggesting momentum has been building...

Toyo Tanso Co., Ltd. ( TSE:5310 ) shareholders are probably feeling a little disappointed, since its shares fell 7.5...

Japan Tobacco Inc. recently reported full-year 2025 results, with sales rising to ¥3,467.68 billion and net income reaching ¥510.18 billion, while also confirming a fiscal year-end 2025 dividend of ¥130.00 per share, up from ¥97.00, payable on March 26, 2026. At the same time, the company guided to slightly lower full-year 2026 dividends of ¥121.00 per share and issued new forecasts calling for ¥3,697.00 billion in revenue and ¥570.00 billion in profit attributable to owners, reshaping...

Updated earnings guidance and what it means for investors SENKO Group Holdings (TSE:9069) has issued consolidated earnings guidance for the fiscal year ending March 31, 2026, outlining expectations that are likely to shape how investors think about the stock. The company is projecting operating revenue of ¥898,000m, operating profit of ¥37,000m, profit attributable to owners of parent of ¥19,200m, and earnings of ¥112.40 per share for the period. See our latest analysis for SENKO Group...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

In February 2026, Maruha Nichiro raised its full-year earnings and year-end dividend guidance for the fiscal year ending March 31, 2026, supported by nine-month sales of ¥837,577 million and expectations of extraordinary gains from selling investment securities and rental real estate, while also booking restructuring-related losses. An interesting angle is that the company’s basic earnings per share forecast rose from ¥115.81 to ¥128.99 even after a three-for-one share split, underlining the...

Nisshinbo Holdings Inc.'s ( TSE:3105 ) earnings announcement last week was disappointing for investors, despite the...

SEIKOH GIKEN Co., Ltd. ( TSE:6834 ) shareholders will have a reason to smile today, with the analysts making...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

In February 2026, Square Enix Holdings reported that nine‑month sales fell to ¥215,455 million from ¥248,519 million a year earlier, while net income edged up to ¥25,607 million and earnings per share from continuing operations also increased. On the same day, the company significantly raised its full‑year profit and earnings-per-share guidance after profitability in Digital Entertainment and royalty income in Rights & Properties surpassed earlier expectations. Next, we’ll examine how this...

Anabuki Kosan (TSE:8928) has posted Q2 2026 results with revenue of ¥44,689 million and basic EPS of ¥235.72, giving investors fresh numbers to weigh against its recent share price of ¥2,588. Over the past few quarters, the company has seen revenue move from ¥38,318 million in Q2 2025 to ¥44,689 million in Q2 2026, while basic EPS shifted from ¥153.58 to ¥235.72 across the same periods. This sets the scene for how you read the latest earnings in light of trailing 12 month net margins and...

WILLs (TSE:4482) has wrapped up FY 2025 with fourth quarter revenue of ¥1,683.8 million and basic EPS of ¥11.04, sitting on top of trailing twelve month revenue of ¥6.1 billion and EPS of ¥41.40 that cap off a year of 25.2% earnings growth and a five year annualized EPS increase of 19.2%. Over the last few quarters, revenue has moved from ¥1,448.6 million in FY 2024 Q4 to ¥1,683.8 million in FY 2025 Q4, while quarterly basic EPS has shifted from ¥6.94 to ¥11.04 over the same period, against a...